TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

News desk

GLP-1 and Tirzepatide News

Regulatory and clinical developments, reported from the original announcement, with the event date kept separate from the publication date.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

This desk reports FDA and regulatory action, trial results, manufacturer and pricing changes, warning letters and coverage news for tirzepatide and GLP-1 care, newest first, each with its primary source and event date. The latest items, checked November 20, 2026, include FDA’s NAION labeling change, Lilly’s ObesityWeek data and a Class II compounded-vial recall.

Answer last reviewed:

NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).

October and November 2026

Ten developments from September 18 to November 9, 2026, newest first. Each item links its primary source; “reported” means we have only press coverage or a press release.

FDA and regulation · event 2026-11-09 · confirmed

No final FDA decision yet on the 503B proposal for tirzepatide

A Federal Register search on November 20, 2026 found no final notice on the FDA’s April 30, 2026 proposal not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list (91 FR 23431). Comments closed on July 30, 2026.

For cash-pay patients: 503A pharmacies that compound for individual prescriptions are not covered by the proposal; programs that rely on 503B outsourcing facilities would need another source if it becomes final.

Source: federalregister.gov

Pricing and access · event 2026-11-06 · confirmed

NexLife lowers its compounded tirzepatide prices

NexLife’s plan pages now list compounded tirzepatide at $129 a month month to month and $125, $119 and $115 a month on 3-, 6- and 12-month plans, and semaglutide at $109, $105, $99 and $95. Its microdose plans followed on November 8 at the same prices.

For cash-pay patients: A 12-month tirzepatide plan now comes to $1,380 at the listed rate. NexLife stays our #1 pick; three programs in our index still list a lower monthly figure.

Source: nexlife.us

Manufacturer and product updates · event 2026-11-06 · confirmed

Lilly and Hims & Hers: Zepbound and Foundayo at Lilly’s self-pay prices on the Hims platform

In a joint release, Lilly and Hims & Hers said Hims patients can buy Zepbound from $299 and Foundayo from $149 at Lilly’s self-pay prices without leaving the platform, and Hims committed not to offer compounded copies of Lilly’s GLP-1s.

For cash-pay patients: Brand prices did not fall; the channel changed. Hims’ own fees for these patients were not stated in the release. Read our analysis.

Source: investors.hims.com

Pricing and access · event 2026-10-15 · confirmed

Medicare Open Enrollment runs to December 7

Medicare Open Enrollment for 2027 plans opened on October 15 and runs to December 7, 2026, per Medicare.gov. The GLP-1 Bridge ($50 a month) runs to December 31, 2027 and covers Wegovy, Foundayo and the Zepbound KwikPen only.

For cash-pay patients: People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1, so compare plan formularies before December 7.

Source: medicare.gov

Pricing and access · event 2026-10-13 · reported

Walmart to cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027

CNBC reported that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after prior authorization, while still not covering GLP-1s for weight loss.

For cash-pay patients: Employees seeking a GLP-1 for weight loss alone stay in the self-pay market. This is from news reporting, not a Walmart plan document.

Source: cnbc.com

Pricing and access · event 2026-10-12 · reported

Ozari Health adds a second compounded GLP-1 plan

A paid press release said Ozari One lists compounded tirzepatide with B12 at $125 a month billed every three months, everywhere except California, and Ozari Select lists tirzepatide from $235 down to $140 a month by plan length.

For cash-pay patients: Ozari is not yet in our price index; these figures come from a press release, not a first-party read.

Source: globenewswire.com

FDA and regulation · event 2026-10-01 · confirmed

FDA updates its page on unapproved GLP-1 drugs

The FDA’s page on concerns with unapproved GLP-1 drugs, current as of October 1, 2026, adds telehealth red flags, a 28-day discard rule for compounded multi-dose GLP-1 vials, and a statement that retatrutide and cagrilintide cannot be used in compounding under federal law.

For cash-pay patients: If you use a compounded multi-dose vial, discard it 28 days after first use, and treat any offer of compounded retatrutide as a red flag.

Source: fda.gov

Pricing and access · event 2026-10-01 · confirmed

Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss

From October 1, 2026, Rhode Island Medicaid no longer covers Foundayo, Saxenda, Wegovy or Zepbound when prescribed solely for weight loss; coverage continues for type 2 diabetes and other approved uses, per a Medicaid plan provider notice.

For cash-pay patients: Affected members must switch to self-pay or to a covered indication with their clinician.

Source: point32health.org

Pricing and access · event 2026-09-29 · confirmed

CMS: Medicare GLP-1 Bridge runs through 2027

CMS’s BALANCE page (modified September 29, 2026) says the Medicare GLP-1 Bridge has been extended through December 31, 2027, and answers an FAQ about “the BALANCE Model not launching in Medicare in 2027”.

For cash-pay patients: Eligible Part D enrollees keep the $50 copay through 2027.

Source: cms.gov

Pharmacy recalls and warning letters · event 2026-09-18 · confirmed

FDA warning letter 738238 to Empower Pharmacy

The FDA’s warning letter to Empower Pharmacy (dated September 18, posted September 22, 2026) says its compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin “appear to be essentially copies of FDA-approved semaglutide and tirzepatide products” and cites insanitary conditions.

For cash-pay patients: Ask any program which pharmacy fills your prescription and whether it has received a warning letter.

Source: fda.gov

Earlier coverage, July 2026 and before

NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).

Categories this desk covers

Category

FDA and regulation

1 published

Category

Clinical trials

1 published

Category

Manufacturer and product updates

1 published

Category

Pricing and access

0 published

Category

Pharmacy recalls and warning letters

0 published

Category

Telehealth and policy

0 published

How tirzepatide compounding became a regulatory question
2022Tirzepatide added to the F2024-10FDA declared the tirzepati2025-02FDA declared the semagluti2025-09-16FDA issued 55+ warning let2026-02-09Novo Nordisk sued Hims & H2026-03-03FDA released 30 further wa2026-03-09Hims & Hers settled with N2026-04-30FDA proposed excluding tir2026-05-01Formal notice published at2026-06-26Comment period extended to2026-07-30Comment period closes
Show this figure as a table
Data table
DateEvent
2022Tirzepatide added to the F
2024-10FDA declared the tirzepati
2025-02FDA declared the semagluti
2025-09-16FDA issued 55+ warning let
2026-02-09Novo Nordisk sued Hims & H
2026-03-03FDA released 30 further wa
2026-03-09Hims & Hers settled with N
2026-04-30FDA proposed excluding tir
2026-05-01Formal notice published at
2026-06-26Comment period extended to
2026-07-30Comment period closes
Every event above links to the agency's own document, not to coverage of it.
What each step actually changedPrimary sources · captured 2026-07-26
What each step actually changed
DateWhat happenedEffect on compounded access
2022Tirzepatide added to the FDA drug shortage listA shortage listing is what permitted compounders to make copies of the approved product.
2024-10FDA declared the tirzepatide shortage resolvedRemoving the shortage listing removed one of the two legal pathways for compounding tirzepatide.
2025-02FDA declared the semaglutide shortage resolvedThe same pathway closed for semaglutide four months later.
2025-09-16FDA issued 55+ warning letters to online GLP-1 sellersLetters cited misleading direct-to-consumer advertising of compounded GLP-1 products.
2026-02-09Novo Nordisk sued Hims & Hers over compounded semaglutidePatent infringement claim following the launch of a low-cost compounded oral product.
2026-03-03FDA released 30 further warning letters to telehealth firmsTargeting claims that compounded GLP-1s are equivalent to the branded products.
2026-03-09Hims & Hers settled with Novo Nordisk and pivoted to branded supplyHims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market.
2026-04-30FDA proposed excluding tirzepatide from the 503B bulks listThe agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway.
2026-05-01Formal notice published at 91 Fed. Reg. 23431Docket 2026-08552 sets out the agency's substance-by-substance reasoning.
2026-06-26Comment period extended to 30 July 2026FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination.
2026-07-30Comment period closesAfter this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026.
A proposal is not a final rule. Nothing here says compounded tirzepatide is unlawful today.
How each category is sourced
How each category is sourced
CategoryPrimary sourceWhat we will not do
FDA and regulationThe agency's own notice or guidance documentReport a summary as the rule
Clinical trialsRegistry entry and peer-reviewed publicationChart a topline figure as a result
Manufacturer updatesThe company's own release, labelled as suchRewrite a release as our conclusion
Pricing and accessThe provider's published page, captured and datedRepeat a discount claim unchecked
Recalls and warning lettersThe published letter or recall noticeImply wrongdoing beyond the document
Telehealth policyStatute, board rule or agency actionGeneralise one state to the country
Stories published
Published — 0 (0%)None yet — 1 (100%)1records
Show this figure as a table
Data table
StatusRecordsShare
Published00%
None yet1100%
Cite this pageCC BY 4.0

Tirzepatide Ranked. “GLP-1 and Tirzepatide News.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/news/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4